A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Public ClinicalTrials.gov record NCT06307431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Study identification
- NCT ID
- NCT06307431
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2024 (Actual)
- Primary completion
- Jan 8, 2028 (Estimated)
- Completion
- Jun 8, 2032 (Estimated)
- Last update posted
- Jul 13, 2026
2024 – 2032
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) | Duarte | California | 91010 | — |
| UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro | Los Angeles | California | 90095 | — |
| UCSF Medical Center at Mission Bay ( Site 0108) | San Francisco | California | 94158 | — |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) | New Haven | Connecticut | 06510 | — |
| Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109) | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute-GU ( Site 0101) | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0100) | New York | New York | 10065 | — |
| Duke Cancer Institute ( Site 0106) | Durham | North Carolina | 27710 | — |
| Abramson Cancer Center ( Site 0107) | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center ( Site 0111) | Philadelphia | Pennsylvania | 19111 | — |
| UT Southwestern Medical Center ( Site 0110) | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06307431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06307431 live on ClinicalTrials.gov.